← Search & browse all drugs
ALIMENTARY TRACT AND METABOLISM › OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS › OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS › Enzymes
verenafusp alfa
A16AB28
Forms & Strengths
- Intravenous solution: 10 mg/mL in single-dose vials
Adult Dosing
- 0.2 mg/kg administered via intravenous infusion once every 2 weeks
- Pre-medication with antihistamines and antipyretics recommended prior to infusion
Pediatric Dosing
- Safety and efficacy in pediatric patients under 18 years have not been fully established
- Use in pediatric patients requires careful weight-based dosing (0.2 mg/kg IV every 2 weeks) under specialist supervision
Indications
- Treatment of Mucopolysaccharidosis type VI (MPS VI, Maroteaux-Lamy syndrome)
Mechanism of Action
- Recombinant human N-acetylgalactosamine 4-sulfatase (arylsulfatase B)
- Catalyzes the hydrolysis of sulfate esters from glycosaminoglycans (dermatan sulfate and chondroitin 4-sulfate)
- Reduces lysosomal accumulation of GAGs in tissues and improves physical endurance
Contraindications
- Life-threatening hypersensitivity reactions to verenafusp alfa or any of its excipients that cannot be successfully managed
Adverse Reactions
- Infusion-associated reactions (fever, chills, rash, urticaria, dyspnea)
- Anaphylaxis
- Nasopharyngitis
- Arthralgia and pain in extremity
- Headache
- Abdominal pain
Drug Interactions
- No formal clinical drug-interaction studies have been conducted
- Avoid concurrent administration with other highly nephrotoxic or hepatotoxic agents when possible due to overlapping clearance pathways
Curated Content: Needs Vetting Before Put to Clinical Use